These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8630428)

  • 21. A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events.
    Haque T; Thomas JA; Parratt R; Hunt BJ; Yacoub MH; Crawford DH
    Transplantation; 1997 Oct; 64(7):1028-34. PubMed ID: 9381525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
    Hoffmann T; Russell C; Vindelov L
    APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depletion of EBV-infected cells in donor marrow by counterflow elutriation.
    Gross TG; Hinrichs SH; Davis JR; Mitchell D; Bishop MR; Wagner JE
    Exp Hematol; 1998 May; 26(5):395-9. PubMed ID: 9590655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
    Papadopoulos EB; Ladanyi M; Emanuel D; Mackinnon S; Boulad F; Carabasi MH; Castro-Malaspina H; Childs BH; Gillio AP; Small TN
    N Engl J Med; 1994 Apr; 330(17):1185-91. PubMed ID: 8093146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.
    Savoldo B; Heslop HE; Rooney CM
    Leuk Lymphoma; 2000 Nov; 39(5-6):455-64. PubMed ID: 11342329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.
    Montagna D; Yvon E; Calcaterra V; Comoli P; Locatelli F; Maccario R; Fisher A; Cavazzana-Calvo M
    Blood; 1999 May; 93(10):3550-7. PubMed ID: 10233908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplant EBV induced lymphoproliferative disorders.
    Lucas KG; Pollok KE; Emanuel DJ
    Leuk Lymphoma; 1997 Mar; 25(1-2):1-8. PubMed ID: 9130609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation.
    Wang XN; Taylor PR; Skinner R; Jackson GH; Proctor SJ; Hedley D; Dickinson AM
    Transplantation; 2000 Aug; 70(3):488-93. PubMed ID: 10949192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.
    Meij P; van Esser JW; Niesters HG; van Baarle D; Miedema F; Blake N; Rickinson AB; Leiner I; Pamer E; Lowenberg B; Cornelissen JJ; Gratama JW
    Blood; 2003 Jun; 101(11):4290-7. PubMed ID: 12576337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
    Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
    Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation.
    Yoshimi A; Tsuge I; Namizaki H; Hoshino Y; Kimura H; Takahashi Y; Watanabe N; Kuzushima K; Kojima S
    Br J Haematol; 2002 Mar; 116(3):710-5. PubMed ID: 11849237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
    Doubrovina E; Oflaz-Sozmen B; Prockop SE; Kernan NA; Abramson S; Teruya-Feldstein J; Hedvat C; Chou JF; Heller G; Barker JN; Boulad F; Castro-Malaspina H; George D; Jakubowski A; Koehne G; Papadopoulos EB; Scaradavou A; Small TN; Khalaf R; Young JW; O'Reilly RJ
    Blood; 2012 Mar; 119(11):2644-56. PubMed ID: 22138512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.
    O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
    Immunol Rev; 1997 Jun; 157():195-216. PubMed ID: 9255631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder.
    Kuzushima K; Kimura H; Hoshino Y; Yoshimi A; Tsuge I; Horibe K; Morishima T; Tsurumi T; Kojima S
    J Infect Dis; 2000 Sep; 182(3):937-40. PubMed ID: 10950793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.
    Haque T; Taylor C; Wilkie GM; Murad P; Amlot PL; Beath S; McKiernan PJ; Crawford DH
    Transplantation; 2001 Oct; 72(8):1399-402. PubMed ID: 11685111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
    Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
    Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
    van Esser JW; Niesters HG; van der Holt B; Meijer E; Osterhaus AD; Gratama JW; Verdonck LF; Löwenberg B; Cornelissen JJ
    Blood; 2002 Jun; 99(12):4364-9. PubMed ID: 12036863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
    Rooney CM; Smith CA; Ng CY; Loftin S; Li C; Krance RA; Brenner MK; Heslop HE
    Lancet; 1995 Jan; 345(8941):9-13. PubMed ID: 7799740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.